
Global Biologics CDMO Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Biologics CDMO market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Biologics CDMO market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Biologics CDMO market include AGC, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, ICON Plc, Samsung Biologics, Toyobo, AbbVie, Lonza Group AG and Thermo Fisher Scientific, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologics CDMO, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biologics CDMO, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics CDMO sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biologics CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biologics CDMO sales, projected growth trends, production technology, application and end-user industry.
Biologics CDMO Segment by Company
AGC
Boehringer Ingelheim
Fujifilm Diosynth Biotechnologies
ICON Plc
Samsung Biologics
Toyobo
AbbVie
Lonza Group AG
Thermo Fisher Scientific
WuXi Biologics
Biologics CDMO Segment by Type
Biological Agent
Biosimilar Drug
Biologics CDMO Segment by Application
Cell Therapy
Drug Development
Others
Biologics CDMO Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Biologics CDMO status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Biologics CDMO market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biologics CDMO significant trends, drivers, influence factors in global and regions.
6. To analyze Biologics CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Biologics CDMO market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics CDMO industry.
Chapter 3: Detailed analysis of Biologics CDMO manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Biologics CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Biologics CDMO in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global Biologics CDMO market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Biologics CDMO market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Biologics CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Biologics CDMO market include AGC, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, ICON Plc, Samsung Biologics, Toyobo, AbbVie, Lonza Group AG and Thermo Fisher Scientific, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biologics CDMO, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biologics CDMO, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics CDMO sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biologics CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biologics CDMO sales, projected growth trends, production technology, application and end-user industry.
Biologics CDMO Segment by Company
AGC
Boehringer Ingelheim
Fujifilm Diosynth Biotechnologies
ICON Plc
Samsung Biologics
Toyobo
AbbVie
Lonza Group AG
Thermo Fisher Scientific
WuXi Biologics
Biologics CDMO Segment by Type
Biological Agent
Biosimilar Drug
Biologics CDMO Segment by Application
Cell Therapy
Drug Development
Others
Biologics CDMO Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Biologics CDMO status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Biologics CDMO market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biologics CDMO significant trends, drivers, influence factors in global and regions.
6. To analyze Biologics CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Biologics CDMO market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics CDMO industry.
Chapter 3: Detailed analysis of Biologics CDMO manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Biologics CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Biologics CDMO in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
191 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Biologics CDMO Sales Value (2020-2031)
- 1.2.2 Global Biologics CDMO Sales Volume (2020-2031)
- 1.2.3 Global Biologics CDMO Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Biologics CDMO Market Dynamics
- 2.1 Biologics CDMO Industry Trends
- 2.2 Biologics CDMO Industry Drivers
- 2.3 Biologics CDMO Industry Opportunities and Challenges
- 2.4 Biologics CDMO Industry Restraints
- 3 Biologics CDMO Market by Company
- 3.1 Global Biologics CDMO Company Revenue Ranking in 2024
- 3.2 Global Biologics CDMO Revenue by Company (2020-2025)
- 3.3 Global Biologics CDMO Sales Volume by Company (2020-2025)
- 3.4 Global Biologics CDMO Average Price by Company (2020-2025)
- 3.5 Global Biologics CDMO Company Ranking (2023-2025)
- 3.6 Global Biologics CDMO Company Manufacturing Base and Headquarters
- 3.7 Global Biologics CDMO Company Product Type and Application
- 3.8 Global Biologics CDMO Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Biologics CDMO Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Biologics CDMO Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Biologics CDMO Market by Type
- 4.1 Biologics CDMO Type Introduction
- 4.1.1 Biological Agent
- 4.1.2 Biosimilar Drug
- 4.2 Global Biologics CDMO Sales Volume by Type
- 4.2.1 Global Biologics CDMO Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Biologics CDMO Sales Volume by Type (2020-2031)
- 4.2.3 Global Biologics CDMO Sales Volume Share by Type (2020-2031)
- 4.3 Global Biologics CDMO Sales Value by Type
- 4.3.1 Global Biologics CDMO Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Biologics CDMO Sales Value by Type (2020-2031)
- 4.3.3 Global Biologics CDMO Sales Value Share by Type (2020-2031)
- 5 Biologics CDMO Market by Application
- 5.1 Biologics CDMO Application Introduction
- 5.1.1 Cell Therapy
- 5.1.2 Drug Development
- 5.1.3 Others
- 5.2 Global Biologics CDMO Sales Volume by Application
- 5.2.1 Global Biologics CDMO Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Biologics CDMO Sales Volume by Application (2020-2031)
- 5.2.3 Global Biologics CDMO Sales Volume Share by Application (2020-2031)
- 5.3 Global Biologics CDMO Sales Value by Application
- 5.3.1 Global Biologics CDMO Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Biologics CDMO Sales Value by Application (2020-2031)
- 5.3.3 Global Biologics CDMO Sales Value Share by Application (2020-2031)
- 6 Biologics CDMO Regional Sales and Value Analysis
- 6.1 Global Biologics CDMO Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Biologics CDMO Sales by Region (2020-2031)
- 6.2.1 Global Biologics CDMO Sales by Region: 2020-2025
- 6.2.2 Global Biologics CDMO Sales by Region (2026-2031)
- 6.3 Global Biologics CDMO Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Biologics CDMO Sales Value by Region (2020-2031)
- 6.4.1 Global Biologics CDMO Sales Value by Region: 2020-2025
- 6.4.2 Global Biologics CDMO Sales Value by Region (2026-2031)
- 6.5 Global Biologics CDMO Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Biologics CDMO Sales Value (2020-2031)
- 6.6.2 North America Biologics CDMO Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Biologics CDMO Sales Value (2020-2031)
- 6.7.2 Europe Biologics CDMO Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Biologics CDMO Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Biologics CDMO Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Biologics CDMO Sales Value (2020-2031)
- 6.9.2 South America Biologics CDMO Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Biologics CDMO Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Biologics CDMO Sales Value Share by Country, 2024 VS 2031
- 7 Biologics CDMO Country-level Sales and Value Analysis
- 7.1 Global Biologics CDMO Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Biologics CDMO Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Biologics CDMO Sales by Country (2020-2031)
- 7.3.1 Global Biologics CDMO Sales by Country (2020-2025)
- 7.3.2 Global Biologics CDMO Sales by Country (2026-2031)
- 7.4 Global Biologics CDMO Sales Value by Country (2020-2031)
- 7.4.1 Global Biologics CDMO Sales Value by Country (2020-2025)
- 7.4.2 Global Biologics CDMO Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.9.2 France Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.16.2 China Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.19.2 India Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Biologics CDMO Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Biologics CDMO Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Biologics CDMO Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 AGC
- 8.1.1 AGC Comapny Information
- 8.1.2 AGC Business Overview
- 8.1.3 AGC Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.1.4 AGC Biologics CDMO Product Portfolio
- 8.1.5 AGC Recent Developments
- 8.2 Boehringer Ingelheim
- 8.2.1 Boehringer Ingelheim Comapny Information
- 8.2.2 Boehringer Ingelheim Business Overview
- 8.2.3 Boehringer Ingelheim Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Boehringer Ingelheim Biologics CDMO Product Portfolio
- 8.2.5 Boehringer Ingelheim Recent Developments
- 8.3 Fujifilm Diosynth Biotechnologies
- 8.3.1 Fujifilm Diosynth Biotechnologies Comapny Information
- 8.3.2 Fujifilm Diosynth Biotechnologies Business Overview
- 8.3.3 Fujifilm Diosynth Biotechnologies Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Fujifilm Diosynth Biotechnologies Biologics CDMO Product Portfolio
- 8.3.5 Fujifilm Diosynth Biotechnologies Recent Developments
- 8.4 ICON Plc
- 8.4.1 ICON Plc Comapny Information
- 8.4.2 ICON Plc Business Overview
- 8.4.3 ICON Plc Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.4.4 ICON Plc Biologics CDMO Product Portfolio
- 8.4.5 ICON Plc Recent Developments
- 8.5 Samsung Biologics
- 8.5.1 Samsung Biologics Comapny Information
- 8.5.2 Samsung Biologics Business Overview
- 8.5.3 Samsung Biologics Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Samsung Biologics Biologics CDMO Product Portfolio
- 8.5.5 Samsung Biologics Recent Developments
- 8.6 Toyobo
- 8.6.1 Toyobo Comapny Information
- 8.6.2 Toyobo Business Overview
- 8.6.3 Toyobo Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Toyobo Biologics CDMO Product Portfolio
- 8.6.5 Toyobo Recent Developments
- 8.7 AbbVie
- 8.7.1 AbbVie Comapny Information
- 8.7.2 AbbVie Business Overview
- 8.7.3 AbbVie Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.7.4 AbbVie Biologics CDMO Product Portfolio
- 8.7.5 AbbVie Recent Developments
- 8.8 Lonza Group AG
- 8.8.1 Lonza Group AG Comapny Information
- 8.8.2 Lonza Group AG Business Overview
- 8.8.3 Lonza Group AG Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Lonza Group AG Biologics CDMO Product Portfolio
- 8.8.5 Lonza Group AG Recent Developments
- 8.9 Thermo Fisher Scientific
- 8.9.1 Thermo Fisher Scientific Comapny Information
- 8.9.2 Thermo Fisher Scientific Business Overview
- 8.9.3 Thermo Fisher Scientific Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Thermo Fisher Scientific Biologics CDMO Product Portfolio
- 8.9.5 Thermo Fisher Scientific Recent Developments
- 8.10 WuXi Biologics
- 8.10.1 WuXi Biologics Comapny Information
- 8.10.2 WuXi Biologics Business Overview
- 8.10.3 WuXi Biologics Biologics CDMO Sales, Value and Gross Margin (2020-2025)
- 8.10.4 WuXi Biologics Biologics CDMO Product Portfolio
- 8.10.5 WuXi Biologics Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Biologics CDMO Value Chain Analysis
- 9.1.1 Biologics CDMO Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Biologics CDMO Sales Mode & Process
- 9.2 Biologics CDMO Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Biologics CDMO Distributors
- 9.2.3 Biologics CDMO Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.